News Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
3.9 ^USD	0.00%		+11.43%	-82.25%

Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Apr. 30	AQ
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”	Apr. 09	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results	Mar. 28	AQ
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tenax Therapeutics to Present at the 36th Annual Roth Conference	Mar. 12	AQ
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024	Feb. 29	AQ
Tenax Therapeutics Secures Global Rights for Levosimendan	Feb. 20	MT
Tenax Therapeutics, Inc. and Orion Corporation Enters into an Amendment to Certain License Agreement	Feb. 20	CI
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan	Feb. 20	AQ
Top Midday Decliners	Feb. 08	MT
Wall Street Set to Open Flat Wednesday; Jobless Claims Fall More Than Expected	Feb. 08	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Investors Await Economic Data	Feb. 08	MT
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering	Feb. 08	AQ
US Futures Marginally Lower Ahead of Jobless Claims, Wholesale Trade Data	Feb. 08	MT
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)	Feb. 07	AQ
Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients	Feb. 07	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 06	MT
Sector Update: Health Care	Feb. 06	MT
Top Midday Gainers	Feb. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tenax Therapeutics, Inc.

Equities

TENX

US88032L6056

Summary

Filters